Balyasny Asset Management logo

Balyasny Asset Management

North America, Illinois, United States, Chicago

Description

Balyasny Asset Management is an asset management firm dedicated to delivering consistent, uncorrelated absolute returns

Investor Profile

Balyasny Asset Management has backed more than 23 startups, with 1 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 8 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series D, Series C, Series A rounds (top funding stages).
  • Majority of deals are located in United States, Sweden.
  • Strong thematic focus on FinTech, Software, Financial Services.

Stage Focus

  • Series D (26%)
  • Series C (13%)
  • Series A (13%)
  • Series F (13%)
  • Series E (9%)
  • Series G (9%)
  • Series B (9%)
  • Series Unknown (9%)

Country Focus

  • United States (96%)
  • Sweden (4%)

Industry Focus

  • Fintech
  • Software
  • Financial Services
  • Big Data
  • Health Care
  • Machine Learning
  • Finance
  • Agriculture
  • Agtech
  • E-commerce
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Balyasny Asset Management frequently co-invest with?

Baillie Gifford
Europe, Edinburgh, City of, United Kingdom, Edinburgh
Co-Investments: 3
Kleiner Perkins
North America, California, United States, Menlo Park
Co-Investments: 3
Google Ventures
North America, California, United States, Mountain View
Co-Investments: 4
BAM Elevate
North America, New York, United States, New York
Co-Investments: 14
Battery Ventures
North America, Massachusetts, United States, Boston
Co-Investments: 3
IVP
North America, California, United States, Menlo Park
Co-Investments: 3
NBCUniversal
North America, New York, United States, New York
Co-Investments: 3
Tiger Global Management
North America, New York, United States, New York
Co-Investments: 3
RRE Ventures
North America, New York, United States, New York
Co-Investments: 3
Fidelity
North America, Massachusetts, United States, Boston
Co-Investments: 5

Which angels does Balyasny Asset Management often collaborate with?

MV
North America, Washington, United States, Seattle
Shared Deals: 2
JD
North America, California, United States, Palo Alto
Shared Deals: 1
SB
North America, California, United States, San Francisco
Shared Deals: 1
SR
North America, California, United States, Los Angeles
Shared Deals: 1
TR
North America, New York, United States, New York
Shared Deals: 1
BM
North America, Texas, United States, Austin
Shared Deals: 1
Shinji Kimura
Asia, Tokyo, Japan, Tokyo
Shared Deals: 1
RM
North America, Massachusetts, United States, Boston
Shared Deals: 1
SB
North America, California, United States, San Francisco
Shared Deals: 1

What are some of recent deals done by Balyasny Asset Management?

Aspen Neuroscience

San Diego, California, United States

Aspen Neuroscience is a biotechnology company that specializes in personalized cell therapies and autologous regenerative medicine.

BiotechnologyMedicalNeurosciencePharmaceuticalTherapeutics
Series CNov 20, 2025
Amount Raised: $115,000,000
Solve Therapeutics

Belmont, California, United States

Solve Therapeutics is a biopharmaceutical company that develops Antibody Drug Conjugate and Bispecific Therapeutics.

BiopharmaBiotechnologyHealth CareTherapeutics
Series UnknownNov 17, 2025
Amount Raised: $120,000,000
Forterra

Clarksburg, Maryland, United States

Forterra delivers autonomous mission systems for defense.

AutomotiveAutonomous VehiclesConsultingMilitaryRoboticsTelecommunications
Series CNov 12, 2025
Amount Raised: $188,000,000
Galecto

Copenhagen, Hovedstaden, Denmark

Galecto is a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer.

BiotechnologyHealth CareHealth Diagnostics
Post Ipo EquityNov 10, 2025
Amount Raised: $284,900,000
Opus Genetics(formerly Ocuphire Pharma)

Farmington Hills, Michigan, United States

Opus Genetics a clinical-stage biopharmaceutical company, develops and commercializes therapies for patients with ophthalmic disorders.

BiopharmaBiotechnologyPharmaceutical
Post Ipo EquityNov 6, 2025
Amount Raised: $23,000,000
Tango Therapeutics

Cambridge, Massachusetts, United States

Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.

BiotechnologyHealth CareMedicalTherapeutics
Post Ipo EquityOct 23, 2025
Amount Raised: $197,000,000
Minerva Neuroscience

Cambridge, Massachusetts, United States

Minerva Neurosciences focuses on the development and commercialization of a portfolio of product candidates to treat CNS diseases.

BiopharmaBiotechnologyHealth CareNeuroscience
Post Ipo EquityOct 21, 2025
Amount Raised: $80,000,000
LEXEO Therapeutics

New York, New York, United States

LEXEO Therapeutics utilizes gene therapy to treat genetically defined cardiovascular and central nervous system diseases.

BiotechnologyLife ScienceTherapeutics
Post Ipo EquityOct 16, 2025
Amount Raised: $135,000,000
Expedition Therapeutics

San Francisco, California, United States

Expedition Therapeutics is a biotechnology company that develops novel therapies for inflammatory and respiratory diseases.

BiotechnologyHealth CareLife ScienceTherapeutics
Series AOct 9, 2025
Amount Raised: $165,000,000
Ovid Therapeutics

New York, New York, United States

Ovid Therapeutic's purpose is to solve intractable medical problems.

BiopharmaBiotechnologyHealth Care
Post Ipo EquityOct 3, 2025
Amount Raised: $81,000,000